---
title: "Eli Lilly is set to initiate a Phase III study of the GLP-1R/GIPR/GCGR agonist, semaglutide, in a head-to-head comparison."
description: "Recently, Eli Lilly registered a Phase III clinical trial for patients with type 2 diabetes on the clinicaltrials.gov website. The trial aims to evaluate the effectiveness and safety of retatrutide co"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/108040168.md"
published_at: "2024-02-16T07:28:08.000Z"
---

# Eli Lilly is set to initiate a Phase III study of the GLP-1R/GIPR/GCGR agonist, semaglutide, in a head-to-head comparison.

> Recently, Eli Lilly registered a Phase III clinical trial for patients with type 2 diabetes on the clinicaltrials.gov website. The trial aims to evaluate the effectiveness and safety of retatrutide compared to semaglutide in the treatment of poorly controlled blood glucose. The study is expected to start on March 20th this year and last for approximately 26 months, with a projected enrollment of 1250 patients. In addition, Eli Lilly is also accelerating the Phase III TRIUMPH series of studies for retatrutide, which aims to evaluate its safety and effectiveness in the treatment of obesity, obstructive sleep apnea, and knee osteoarthritis.

Zhitong App has learned that recently, the clinicaltrials.gov website showed that Eli Lilly (LLY.US) has registered a randomized, multicenter, open-label Phase III clinical trial for the GLP-1R/GIPR/GCGR triple agonist retatrutide. The trial aims to evaluate the efficacy and safety of retatrutide compared to semaglutide in the treatment of poorly controlled type 2 diabetes patients with or without metformin in combination with a sodium-glucose cotransporter 2 inhibitor (SGLT2i).

It is understood that the study is expected to start on March 20th of this year and will be completed on December 11th, 2026 for the primary research and on March 30th, 2027 for the entire study. The study will last for approximately 26 months and may include up to 24 visits, with an estimated recruitment of 1,250 patients. The primary endpoint is the change in patients' hemoglobin A1c (HbA1c) values from baseline at week 80.

Currently, Eli Lilly (LLY.US) is also accelerating the Phase III TRIUMPH series of studies for retatrutide, which includes four key registration trials. These trials aim to evaluate the safety and efficacy of retatrutide for chronic weight management in obese and overweight patients, obstructive sleep apnea (OSA), and osteoarthritis (OA) of the knee joint.

![Image](https://imageproxy.pbkrs.com/http://img.zhitongcaijing.com/images/contentformat/43a5e62a2bbff77ff36f5c1a8f646f98.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg)

### Related Stocks

- [GLP.US - Global Partners LP](https://longbridge.com/en/quote/GLP.US.md)
- [LLY.US - Eli Lilly](https://longbridge.com/en/quote/LLY.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Eli Lilly (LLY) Builds $1.5 Billion Inventory of Weight-Loss Pill | Eli Lilly (LLY) has prepared a $1.5 billion inventory of its new weight-loss pill, Orforglipron, ahead of its anticipate | [Link](https://longbridge.com/en/news/276070062.md) |
| Are Wall Street Analysts Predicting Keysight Technologies Stock Will Climb or Sink? | Are Wall Street Analysts Predicting Keysight Technologies Stock Will Climb or Sink? | [Link](https://longbridge.com/en/news/276353077.md) |
| Broderick Brian C Purchases 985 Shares of Eli Lilly and Company $LLY | Broderick Brian C increased its stake in Eli Lilly and Company (NYSE: LLY) by 15.1% in Q3, acquiring 985 additional shar | [Link](https://longbridge.com/en/news/276435096.md) |
| Puzo Michael J Has $320,000 Stock Position in Novo Nordisk A/S $NVO | Puzo Michael J significantly reduced its stake in Novo Nordisk A/S (NYSE:NVO) by 86.9% in Q3, now holding 5,775 shares v | [Link](https://longbridge.com/en/news/276447697.md) |
| Eli Lilly Breaks New Ground In Crohn's Disease Treatment | Eli Lilly (LLY) announced significant Phase 3 results for its Crohn's disease treatment, Omvoh, with over 90% of patient | [Link](https://longbridge.com/en/news/276442344.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
